These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23510657)

  • 1. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model.
    Gaba RC; Yap FY; Martinez EM; Li Y; Guzman G; Parvinian A; van Breemen RB; Kumar N
    J Vasc Interv Radiol; 2013 May; 24(5):744-50. PubMed ID: 23510657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
    Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
    J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
    Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
    Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
    Chatziioannou AN; Siskos AP; Loxas D; Kavatzas N; Agrogiannis G; Fokas D; Malagari K; Kostomitsopoulos NG; Tsigkou O; Tamvakopoulos C
    J Vasc Interv Radiol; 2013 Nov; 24(11):1657-63.e1. PubMed ID: 24060438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors.
    Gaba RC; Baumgarten S; Omene BO; van Breemen RB; Garcia KD; Larson AC; Omary RA
    J Vasc Interv Radiol; 2012 Feb; 23(2):265-73. PubMed ID: 22178040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model.
    Seidensticker M; Streit S; Nass N; Wybranski C; Jürgens J; Brauner J; Schulz N; Kalinski T; Seidensticker R; Garlipp B; Steffen I; Ricke J; Dudeck O
    Diagn Interv Radiol; 2016; 22(4):378-84. PubMed ID: 27328720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study.
    Lee IJ; Lee M; Kim SJ; Kim YK; Won JY; Chung JW
    J Vasc Interv Radiol; 2018 Aug; 29(8):1078-1084. PubMed ID: 29910164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.
    Elkhadragy L; Khabbaz RC; Muchiri RN; Totura WM; Samuelson JP; Whiteley HE; van Breemen RB; Lokken RP; Gaba RC
    J Vasc Interv Radiol; 2022 Oct; 33(10):1213-1221.e5. PubMed ID: 35850455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
    Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
    J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
    Choi JW; Park JH; Cho HR; Chung JW; Kim DD; Kim HC; Cho HJ
    Sci Rep; 2017 Apr; 7(1):554. PubMed ID: 28373713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
    Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
    J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
    Hsiao WD; Peng CY; Chuang PH; Lai HC; Cheng KS; Chou JW; Chen YY; Yu CJ; Feng CL; Su WP; Chen SH; Kao JT
    BMC Gastroenterol; 2016 Apr; 16():50. PubMed ID: 27117280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
    Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
    Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
    Matsui O
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():3-13. PubMed ID: 22873623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
    Zhang L; Liu FY; Fu JX; Duan F; Fan QS; Wang MQ
    Int J Clin Exp Pathol; 2014; 7(11):7775-81. PubMed ID: 25550815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.